(Q34558808)

3 August 2017

1 reference

title

The medical benefit of 5-HT research (English)

1 reference

3 August 2017

Brian J Jones

1

1 reference

3 August 2017

Thomas P Blackburn

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Pharmacology, Biochemistry and Behavior

3 August 2017

published in

1 reference

3 August 2017

volume

71

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

555-568

1 reference

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The hyperserotonemia of autism

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Buspirone: future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

How does pindolol improve antidepressant action?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

A review of central 5-HT receptors and their function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The serotonin hypothesis of aggression revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Current advances and trends in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-ht6 receptors as emerging targets for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Drug treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

New insights into the biology of schizophrenia through the mechanism of action of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Role of serotonin in memory impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Agony and ecstasy: a review of MDMA effects and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Pharmacology and clinical experience with alosetron

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

SSRIs in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT modifiers as a potential treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The role of serotonin in craving: from basic research to human studies

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Current and emerging second-generation triptans in acute migraine therapy: a comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Review of current treatment in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Irritable bowel syndrome: new agents targeting serotonin receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

New drugs in the management of the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Irritable bowel syndrome: new pharmaceutical approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Drug treatment for PTSD. Answers and questions

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Serotonin and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Drugs which antagonize 5-hydroxytryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Two kinds of tryptamine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Advances in the pharmacotherapy of migraine. How knowledge of pathophysiology is guiding drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

SSRIs in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Selective serotonin reuptake inhibitors in affective disorders--II. Efficacy and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Pharmacology of appetite suppression.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The neuropathology of schizophrenia. A critical review of the data and their interpretation

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Generalized anxiety disorder. An important clinical concern

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Serotonin autoreceptor function and antidepressant drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Serotonergic Function in Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Mode of action of the anti-migraine drug sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Preclinical Studies on the Anti-Migraine Drug, Sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Is there a basis for novel pharmacotherapy of autism?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The question of feedback at the somadendritic region and antidepressant drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Serotonergic basis of antipsychotic drug effects in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Paroxetine in the treatment of premature ejaculation

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The role of drug therapy in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Long term psychiatric and cognitive effects of MDMA use.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT system and cognition

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Buspirone augmentation of sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2Asites for PCP-induced locomotion in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Ecstasy (MDMA): a review of its possible persistent psychological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Resolution of fluoxetine-induced sexual dysfunction with the 5-HT3 antagonist granisetron.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Diverse signalling by 5-hydroxytryptamine (5-HT) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Double-blind clinical trial of sertraline treatment for alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT1B receptor knock out--behavioral consequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Importance of h5-HT1B receptor selectivity for 5-HT terminal autoreceptor activity: an in vivo microdialysis study in the freely-moving guinea-pig

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Effects of SSRIs on sexual function: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT2C receptor activation decreases appetite and body weight in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The catecholamine hypothesis of affective disorders: a review of supporting evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

The analgesic effects of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Control of dorsal raphé 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

High 5HT2A receptor occupancy in M100907-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

5-HT7 receptors: current knowledge and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Advances in use of the 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Pharmacological agents for the treatment of urinary incontinence due to overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Serotonergic receptor subtypes and hallucinogen-induced stimulus control

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2801%2900745-6

7 January 2021

10.1016/S0091-3057(01)00745-6

Identifiers

DOI

1 reference

3 August 2017

1 reference